Willow Biosciences Inc (CANSF)

[Aladdin80]

Correction, this is not news of a new patent, it's news of a new patent filing. This is a non event.

[msheppard4]

Good news

new patent

[Aladdin80]

This company is really just awful. They burned $4M in the quarter bringing their total cash down from $10.5M to $6.5M. At the current burn rate they'll be broke within 2 operating quarters. Clearly revenue isn't getting them there as they dropped from $274K to $135K quarter to quarter. If they execute another cash raise they'll need massive dilution at 0.07-0.08 USD. They're consistently "progressing", but nothing that is material enough to move the needle in the right direction. Consider selling positions now or near-term before next round of rock bottom financing is needed. Given that firms don't borrow when they're broke that news could come in a matter of weeks.

[molee]

So , big volume down day today . Earnings report that bad ?

Any hopes for a rebound here ?

Enjoy the weekend >> M

[Aladdin80]

Appreciate your optimism as we all need that on occasion, but I'm actually more concerned in this company after the recent release. After that digging I came up with a lot of red flags on the company, the size of the operation, the CEO, a private residence as the corp address in FL, barely any revs to speak of. I've been down this road before w/penny stocks and it screams corruption. Just my two pessimistic cents.

[janeyH]

At least we’ve been holding double digits!!

How’s that for finding a bright side?

[Aladdin80]

I can't stop laughing. A "team of experts" is quite the wild exaggerations for a staff of 3 people.

The corporate address pulls up a private residence in West Palm, FL. Lol. What a scam. I hope they can manage to pump this thing back to levels close enough to be worth bailing. I seriously can't stop laughing at how glittery they made this announcement sound and it's with a partner running a business from his house.

State of Inc: Florida
Location Type: Single
Revenue: $ 73,490
Employees Here: 3
Facility Size: N/A

[janeyH]

the must be 3 old dudes ...

ABOUT SANDHILL ONE
A Team of Experts
Sandhill One is a Florida LLC that was founded by three veterans of the pharmaceutical industry with a combined 70 years in R&D, manufacturing, and business management

[janeyH]

they have NOTHING to do with Sand Hill Road

[Aladdin80]

Ok, I retract my statement from yesterday. For now, I'll call this NR fluff. I almost laughed when after looking into it I saw that SandHill has a whopping 3 people on payroll, each presumably making well over the minuscule <$100k in annual revs. Insert sad face emoji.

[janeyH]

Interested yes, not too excited yet

[Aladdin80]

Dare I be excited here? I may have to begin paying attention again to little ol' Willow. Still holding enough shares to actually care about them executing and finally generating some well needed revs.

[janeyH]

a little life left in the old stock

[molee]

Lurker here ... Nice bump today . This seems like good news to me ...

MOUNTAIN VIEW, Calif., April 18, 2023

Commercial agreement follows the early success on the development phase of the UDCA program with Sandhill One

Solid execution on development phases leads to execution of agreement; illustrates company progress against targeted milestones anticipated for 2023 to expand company growth

Willow's unique combination of strain engineering, precision fermentation and its newly developed BioOxi™ bio-oxidation platform has accelerated the timeline to reach commercial agreement

MOUNTAIN VIEW, Calif., April 18, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW); (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announces execution of a commercial agreement with Sandhill One, LLC ("Sandhill"). Willow previously announced the successful results from the application of its BioOxiTM bio-oxidation platform to the development of a key step for the large volume active pharmaceutical ingredient ("API"), ursodeoxycholic acid ("UDCA"), used in nutraceutical and pharmaceutical products.

Willow Biosciences Inc. Logo (CNW Group/Willow Biosciences Inc.)

UDCA is used as a medication for the management and treatment of cholestatic liver disease and gallstone conditions, and as an important intermediate for production of tauroursodeoxycholic acid (TUDCA), a key API in a combination therapy recently approved in Canada and the United States for treatment of amyotrophic lateral sclerosis (ALS). The process under development between the Company and Sandhill represents a step-change in the production of UDCA: it is expected to be lower in cost and will not rely on animal-sourced raw materials, unlike most current manufacturing of UDCA and other cholic acids.

Willow now expects that, upon completion of its development project with Sandhill and assuming the optimized enzyme is utilized in Sandhill's end-market manufacture, following receipt of milestone payments, it may receive a reasonably significant percent of Sandhill's end-market revenues. This royalty-bearing agreement would be more attractive than Willow originally expected and highlights the Company's rapid steps to bring in nearer term revenue.

"We are very pleased to have executed this agreement so quickly following our partnership with Sandhill and highly appreciate their collaborative work with us to create an alternative, more sustainable and less expensive source of UDCA to battle several significant health conditions in an era of escalating healthcare costs," said Dr. Chris Savile, Willow's President and CEO. "I am also proud of our R&D team's hard work and accomplishments to bring this commercial agreement to fruition, which further endorses our reputation in helping our partners sustainably solve their commercial challenges and in bringing cost-effective innovation to their end markets."

"We are delighted with Willow's rapid progress in successfully executing the development phases of this project. Our confidence in their results and the ensuing value has accelerated our decision to put in place a mutually rewarding commercial agreement," said J. Gregory Reid, Ph.D., Chief Scientific Officer of Sandhill. "We look forward to converting this value-added technology package into commercial reality and broadening the availability of sustainably sourced UDCA to support better health for people and our planet."

[Aladdin80]

Ok, is there something brewing? I've only been waiting a few years. Let's get some orders.

[janeyH]

sure can

$0.0672
-$0.0121 (-15.259%)
Bid x Size
$0.0411 x 10,000

[Aladdin80]

I feel like it can. Painful indeed. I watched another cannabinoid based biotech, TBP, crawl all the way back to current levels of 0.017. Wish I didn't have so many shares of this junk. Well junk for now at least that is until they commercialize something. Anything.

[janeyH]

Micro Cap ($9.77M)

Are we there yet, the bottom? Can it go ANY LOWERS??????????????????????

[Aladdin80]

Now that's actually quite funny

[janeyH]

They do!

[blue_skies]

Janey,
Does willow biosciences have a full time CEO? (LOL)

[janeyH]

Volume
200

STAND BACK!!!!!!!!!!!!!!!!! SHE'S GONNA BLOW!!!!!!!!!!!!!!!!!!!!!

[janeyH]

i think that was actually the CeO or his brother. they had a little janey-fetish going i think. if they only knew …

[Aladdin80]

Well Janey I'll be patiently waiting there with you.

So whatever happened to that uber bullish fella on this forum that was constantly sending you messages? Did he pull a David Copperfield disappearing act after pumping this for over 2 years while it constantly fell lower and lower?

[janeyH]

Hello Al, maybe things will pick up after the new year when tax selling eases off and some of those little yeast get on with making some asthaxathin

[Aladdin80]

Well I see that none of the recent news has made any difference to the broader market. Also, more officers/execs have purchased commons which is typically a sign of strength, but no major announcements and no positive uptrends in SP. This stock is surely a strange one.

[janeyH]

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
BY PR Newswire
— 7:00 AM ET 11/07/2022
CALGARY, AB AND MOUNTAIN VIEW, Calif, Nov. 7, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today announced that it will host a webcast investor presentation on Thursday, November 10th at 2:00 PM EST.

During the webcast, Dr. Peter Seufer-Wasserthal, Willow's President and Chief Executive Officer and Troy Talkkari, Vice President of Corporate Development will provide a presentation that will cover key areas of Willow's business. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

To listen to the webcast or to ask questions during the live event, please pre-register at the following link:

https://event.webcasts.com/starthere.jsp?ei=1576448&tp_key=c06ce0c9af

An archived version of the webcast and presentation will be available on the Company's website, www.willowbio.com/#investors.

About Willow Biosciences Inc. (CANSF)

[janeyH]

Q rept our ... yawn

[janeyH]

CALGARY, AB and MOUNTAIN VIEW, Calif., Oct. 12, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce that it has completed proof of concept work, and has started yeast strain optimization and process development toward commercial production of astaxanthin, a powerful, naturally occurring, antioxidant compound that is used in diverse industries such as animal feed, food & nutrition, and cosmetics.

Willow Biosciences Inc. logo (CNW Group/Willow Biosciences Inc.)

"We are pleased to add astaxanthin as the next functional ingredient to our product portfolio", said Dr. Peter Seufer-Wasserthal, Willow's Interim President and Chief Executive Officer. "Astaxanthin meets all the criteria for development using our fully integrated FutureGrownTM technology platform. It has a large addressable market, with the majority of product currently supplied being chemically produced using a petroleum feedstock. Willow offering a natural, clean, sustainably produced product allows not only penetration of the current large volume market, but expansion of the market for human health & wellness, where there is currently no high-purity, cost effective bio-based product available."

[janeyH]

glimmer of hope from the Canopy results

[Aladdin80]

I'll take anything positive at this stage. It's been an absolutely awful perpetual downtrend since as long as I can remember.

[janeyH]

and a little more insider buying this week ... a sign?

[Aladdin80]

One thing that I did just notice which isn't significant is that three insiders just purchased a total of ~1,000,000 common shares in the open market w/Archibald just buying 500,000 yesterday.

[Aladdin80]

Nope, and why should they. A little movement recently, but still nothing but a yawn fest. Looks like most have vacated positions as the commentary that I previously tracked a while ago is down to chatter. As you know, one could literally spend a week talking to themselves on this forum.

[janeyH]

absolutely no on e gives a shit

$0.0921
-$0.0069 (-6.97%)
Bid x Size
$0.0791 x 36,000
Ask x Size
$0.0848 x 85,500
Volume
0
90 Day Avg. Vol.
38,464
Open
$0.0959
Previous Close 08/31/2022
$0.0921

[janeyH]

the results are soooo badd they dont even include them in the release:

Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended June 30, 2022 are available on SEDAR at www.sedar.com.

[janeyH]

how much lower can it go, really?

Market cap. Micro Cap ($13.52M)

[janeyH]

going to single digits usd - fugh!

[Aladdin80]

Lol, surely wasn't me buying anything that rhymes with pillow.

[janeyH]

New CEO, might be extended to 2026

[janeyH]

Fare thee well, Trevois ...

CALGARY, AB and MOUNTAIN VIEW, Calif. , July 18, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, is pleased to announce that the Board of Directors has appointed Dr. Peter Seufer-Wasserthal as Interim President and Chief Executive Officer, effective July 17, 2022, in connection with Trevor Peters' retirement as President and CEO. Mr. Peters will continue to be a Director of the Company. In addition to the above mentioned changes, Ms. Barbara Munroe, a Director of the Company, has been appointed as Lead Independent Director.

[janeyH]

well, given volume was ZERO yesterday, that takes only one

[janeyH]

there is soooo much funny biz in stock, i should just quit ...

ask was at .1234. put in a bid at .1234, before it executed, bid moved to .1235. what weird games ppl play in the stocks.

[janeyH]

Was this you ... ?

Volume
950

[janeyH]

interesting yardstick for that analysis!!

[Aladdin80]

There's pathetic volume and then there's Willow volume. Less shares trade daily on this stock than the number of our youth that trade their genders.

[Aladdin80]

I don't know, but I could really use some "real" material news from this company. If they had some and clawed back over even .50 I'd then have to decide if I trust them longer term or would I bail.

[janeyH]

Market cap. Micro Cap ($17.40M), crazy.

will they EVER have a real news to report

[janeyH]

feels like flippers flippin

[Aladdin80]

Yeah about $15.2 is what I had noted last week which is absurd. I can't wrap my head around how the market values them at less than the hard cash they have in hand.